Novel target differentiated from NASH competitors

  • Activation drives lipogenesis and steatohepatitis
  • Induced by ER stress and TNF
  • Proteolytic activation of S1P and activation of SREBP
  • Inhibition halts progression of NASH
  • Therapeutics against caspase-2 can be used to prevent and treat stress-driven fatty liver diseases
  • SBDD and biologic technologies can be applied